Related Experiment Video
Updated: Jan 16, 2026
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID): three Case Reports and systematic
Quanying Ji1, Shuyuan Yu2, Xia Zhou2
1School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Objective:
This study aimed to investigate the clinical characteristics and personalized treatment strategies for proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Methods:
A retrospective analysis was conducted on the clinical features, pathological characteristics, and treatment regimens of three PGNMID patients.
Conclusion:
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits patients commonly present with proteinuria, hematuria, and renal insufficiency. Pathologically, light microscopy predominantly reveals a membranoproliferative glomerulonephritis (MPGN) pattern, with IgG3κ being the most prevalent immunohistochemical subtype. Current guidelines recommend the BCD regimen (bortezomib, cyclophosphamide, dexamethasone) as first-line therapy. Daratumumab may be a safe and effective therapeutic option for PGNMID; however, clinical decision-making should comprehensively consider patient age, renal function status, treatment tolerance, and other factors.
